Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. demonstrates a strong growth trajectory supported by a robust pipeline of contracts, with a notable $650 million still pending despite recently securing a $500 million deal. The company's expansion in specialty care management services aligns with increasing demand for value-based care, particularly in oncology and cardiology, where a significant portion of the total addressable market remains untapped. Additionally, recent contract adjustments that incorporate risk corridors and cap-rate adjustments reflect Evolent's proactive approach to adapting to industry trends, ensuring continued revenue growth potential.

Bears say

Evolent Health is facing significant challenges as its revenue composition is expected to shift, with non-enhanced revenues declining from approximately $285 million to $170 million between 2025 and 2026. Anticipated declines in Medicaid and Exchange membership could result in a combined EBITDA reduction of $18 million to $25 million, exacerbating financial pressures on the company. Additionally, the company forecasts a sequential revenue decline of $8 million to $18 million in Q4, which raises further concerns about its ability to maintain profitability in a landscape marked by diminishing high-margin enrollment.

Evolent Health (EVH) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 15 analysts, Evolent Health (EVH) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.